Tectonic Therapeutic, Inc. (TECX) — SEC Filings
Tectonic Therapeutic, Inc. (TECX) — 45 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 17 8-K, 7 SC 13G/A, 6 10-Q.
View Tectonic Therapeutic, Inc. on SEC EDGAR
Overview
Tectonic Therapeutic, Inc. (TECX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Tectonic Therapeutic, Inc. (TECX) reported a net loss of $19.0 million for the three months ended September 30, 2025, and a net loss of $54.9 million for the nine months ended September 30, 2025. This represents an increase from the net loss of $17.7 million and $45.6 million for the comparable peri
Sentiment Summary
Across 45 filings, the sentiment breakdown is: 2 bearish, 41 neutral, 2 mixed. The dominant filing sentiment for Tectonic Therapeutic, Inc. is neutral.
Filing Type Overview
Tectonic Therapeutic, Inc. (TECX) has filed 6 10-Q, 17 8-K, 1 DEF 14A, 2 S-1, 2 10-K, 7 SC 13G/A, 3 SC 13D/A, 3 SC 13G, 3 SC 13D, 1 8-K/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (45)
Risk Profile
Risk Assessment: Of TECX's 34 recent filings, 2 were flagged as high-risk, 19 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$54.9M |
| EPS | -$1.02 |
| Cash Position | $268.4M |
Key Executives
- Marcella K. Ruddy
- Timothy A. Springer
- Michael K. Bradshaw, Jr.
- Jonathan G. Weaver
- Jean-Philippe Kouakou-Zebouah
- Jonathan Flint
Industry Context
The biotechnology industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Tectonic Therapeutic operate in a competitive landscape where innovation is key, but success is often dependent on securing substantial funding to advance drug candidates through clinical trials and towards commercialization.
Top Tags
biotech (12) · ownership-change (7) · sec-filing (6) · financials (5) · 10-Q (4) · Biotechnology (3) · corporate-governance (3) · 8-k (3) · schedule-13d (3) · amendment (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $54.9M | for the nine months ended September 30, 2025, an increase from $45.6M in 2024 |
| Accumulated Deficit | $203.5M | as of September 30, 2025, indicating significant historical losses |
| Private Placement Proceeds | $173.1M | net proceeds from common stock issuance in February 2025, boosting liquidity |
| Cash and Cash Equivalents | $268.4M | as of September 30, 2025, up from $141.2M at December 31, 2024 |
| Research and Development Expenses | $47.1M | for the nine months ended September 30, 2025, up from $32.2M in 2024 |
| Common Shares Outstanding | 18,716,280 | as of November 3, 2025, reflecting dilution from capital raises |
| Net Loss Per Share (Diluted) | $1.02 | for the three months ended September 30, 2025, compared to $1.20 in 2024 |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating pre-commercial stage |
| Research and Development Expense | $45.4M | for the six months ended June 30, 2025, reflecting ongoing clinical development |
| General and Administrative Expense | $10.3M | for the six months ended June 30, 2025 |
| Reporting Date | 2025-03-31 | As of this date, financial details are reported. |
| Prior Year End | 2024-12-31 | Comparison point for financial data. |
| Fiscal Year End | 2024-12-31 | Indicates the end of the company's financial reporting year. |
| Previous Fiscal Year End | 2023-12-31 | Provides a comparative financial period. |
| Filing Date | 20250326 | The date Tectonic Therapeutic, Inc. submitted its S-1 filing. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Tectonic Therapeutic, Inc. (TECX)?
Tectonic Therapeutic, Inc. has 45 recent SEC filings from Jan 2024 to Nov 2025, including 17 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TECX filings?
Across 45 filings, the sentiment breakdown is: 2 bearish, 41 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Tectonic Therapeutic, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Tectonic Therapeutic, Inc. (TECX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Tectonic Therapeutic, Inc.?
Key financial highlights from Tectonic Therapeutic, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TECX?
The investment thesis for TECX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Tectonic Therapeutic, Inc.?
Key executives identified across Tectonic Therapeutic, Inc.'s filings include Marcella K. Ruddy, Timothy A. Springer, Michael K. Bradshaw, Jr., Jonathan G. Weaver, Jean-Philippe Kouakou-Zebouah and 1 others.
What are the main risk factors for Tectonic Therapeutic, Inc. stock?
Of TECX's 34 assessed filings, 2 were flagged high-risk, 19 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Tectonic Therapeutic, Inc.?
Forward guidance and predictions for Tectonic Therapeutic, Inc. are extracted from SEC filings as they are enriched.